Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma.

ABSTRACT:

Background

Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.

Methods

This clinical study was a multicentre, retrospective, observational study at two hospitals. Patients aged ≥18 years diagnosed with severe asthma treated with benralizumab were included. Elderly patients were defined as those aged 70 years or older. Efficacy and safety were then analyzed in elderly and non-elderly patients. The primary endpoints were the annual number of asthma exacerbations for efficacy and the discontinuation rate due to adverse events for safety.

Results

Between August 2016 and October 2022, 61 patients were enrolled; 10 patients were exclude

SUBMITTER: Somekawa K 

PROVIDER: S-EPMC11285213 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature